ライフサイエンスコーパス: cysteinyl leukotriene

1 educes antigen-induced secretion of PGD2 and cysteinyl-leukotriene.

2 , whereas mRECs produced both LTB(4) and the cysteinyl leukotrienes.

3 nflux through CRAC channels and responded to cysteinyl leukotrienes.

4 -5, interleukin-13, eotaxin, prostanoids and cysteinyl leukotrienes.

5 ed in the generation of both prostanoids and cysteinyl leukotrienes.

6 ntrast, M1 macrophages gave higher levels of cysteinyl leukotrienes.

7 intracellular parent of the proinflammatory cysteinyl leukotrienes.

8 piratory tissues and excessive production of cysteinyl leukotrienes.

9 cterise the responsiveness of human P2Y12 to cysteinyl leukotrienes.

10 ial killing, and production of TNF-alpha and cysteinyl leukotrienes.

11 classes of molecules: uracil-nucleotides and cysteinyl-leukotrienes.

12 lasses of human G protein-coupled receptors, cysteinyl leukotriene 1 (CysLT(1)) and CysLT(2) receptor

13 in a strain with targeted disruption of the cysteinyl leukotriene 1 (CysLT(1)) receptor suggested th

14 rienes (CysLTs) are mediated by 2 receptors: cysteinyl leukotriene 1 receptor (CysLT1R) and cysteinyl

15 study, we determined whether montelukast, a cysteinyl leukotriene 1 receptor antagonist, could preve

16 The cysteinyl leukotriene(1) (CysLT(1)) receptor antagonist

17 rienes, which are competitive antagonists of cysteinyl-leukotriene-1 receptors, are the first new cla

18 ulted in the generation of 23.9 +/- 6.0 pmol cysteinyl leukotrienes/10(6) eosinophil-lineage cells (m

19 hore-induced production of 94.6 +/- 9.0 pmol cysteinyl leukotrienes/10(6) eosinophil-lineage cells (n

20 steinyl leukotriene 1 receptor (CysLT1R) and cysteinyl leukotriene 2 receptor (CysLT2R).

21 decreased eicosanoid biosynthesis, including cysteinyl leukotrienes (80% mean decrease) that mediated

22 Prominent among such signals are the cysteinyl leukotrienes, a family of potent proinflammato

23 Pharmacological studies have determined that cysteinyl leukotrienes activate at least two receptors,

24 Cysteinyl leukotrienes activate the cysteinyl leukotrien

25 cellular calcium mobilization in response to cysteinyl leukotriene administration was detected in hum

26 nvolved in the extrusion of reduced folates, cysteinyl leukotrienes and bile acids, and the molecular

27 kast and loratadine inhibited the release of cysteinyl leukotrienes and histamine into the airways, b

28 reatments being developed beyond blockade of cysteinyl leukotrienes and IgE and improvements in inhal

29 Cysteinyl leukotrienes and oxidative stress have both be

30 ophagoides farinae through the generation of cysteinyl leukotrienes and proinflammatory cytokines, re

31 and suggest downstream provocative roles for cysteinyl leukotrienes and protective roles for SOCS3 in

32 to leukotriene D(4), the most potent of the cysteinyl leukotrienes and the immediate precursor of le

33 require 5-lipoxygenase-mediated synthesis of cysteinyl leukotrienes and their efflux from the cell.

34 abelled LTD4 binding to this receptor by the cysteinyl leukotrienes and three structurally distinct c

35 AM phagocytosis, killing, and production of cysteinyl leukotrienes and TNF-alpha are restored in the

36 itis model accompanied by impaired levels of cysteinyl-leukotrienes and prostaglandin E2.

37 ncreases in metabolites of prostaglandin D2, cysteinyl leukotrienes, and isoprostanes following the c

38 proinflammatory mediators, including IL-13, cysteinyl leukotrienes, and PGD(2), and airway hyperresp

39 andomized, double-blind crossover study, the cysteinyl leukotriene antagonist montelukast and antihis

40 Combined exposure to SB201146 and to the cysteinyl leukotriene antagonist SKF104353 did not have

41 tors occurs during EIB and how histamine and cysteinyl leukotriene antagonists alter the airway event

42 In lower animals and humans, the cysteinyl leukotrienes are among the most potent airway

43 Cysteinyl leukotrienes are established mediators of bron

44 Cysteinyl leukotrienes are increased during acute lung i

45 Our findings that cysteinyl leukotrienes are involved in regulating airway

46 Cysteinyl leukotrienes are involved in the pathogenesis

47 The cysteinyl leukotrienes are potent mediators of airway na

48 The cysteinyl leukotrienes are potent proinflammatory mediat

49 Cysteinyl leukotrienes are primarily produced by mast ce

50 the pathophysiological effects of individual cysteinyl leukotrienes are primarily unknown.

51 trong scientific rationale for their use, as cysteinyl-leukotrienes are increased in asthma and can m

52 The paracrine signal was identified as a cysteinyl leukotriene because 1) RNAi knockdown or pharm

53 The antioxidant GSH and the pro-inflammatory cysteinyl leukotriene C4 have been identified as key phy

54 ry and immunomodulatory mediators, including cysteinyl leukotrienes, chemokines, and cytokines, which

55 It produces cysteinyl leukotrienes (cLT), and cLT have been implicat

56 Sputum cysteinyl-leukotrienes concentrations were significantly

57 feedback cascade involving CRAC channels and cysteinyl leukotrienes constitute a novel mechanism for

58 For example, cysteinyl leukotrienes contract airway smooth muscle, in

59 Cysteinyl leukotrienes contribute to Th2-type inflammato

60 As cysteinyl leukotriene (cys-LT) biosynthesis is a charact

61 Dermatophagoides farinae (Df) that mediates cysteinyl leukotriene (cys-LT) generation from pulmonary

62 il infiltration, and increased levels of the cysteinyl leukotriene (cys-LT) leukotriene C(4) (LTC(4))

63 ) C4 synthase (LTC4S), which is required for cysteinyl leukotriene (cys-LT) production.

64 s, and induces a calcium flux in response to cysteinyl leukotrienes (cys-LTs) and uridine diphosphate

65 The cysteinyl leukotrienes (cys-LTs) are 5-lipoxygenase path

66 The cysteinyl leukotrienes (cys-LTs) are a family of potent

67 The cysteinyl leukotrienes (cys-LTs) are a family of potent

68 Cysteinyl leukotrienes (cys-LTs) are potent inflammatory

69 The cysteinyl leukotrienes (cys-LTs) are proinflammatory lip

70 The cysteinyl leukotrienes (cys-LTs) are three structurally

71 Cysteinyl leukotrienes (cys-LTs) can mediate Th2 immunit

72 receptor-2 (FPR-2), triggered the release of cysteinyl leukotrienes (cys-LTs) from eosinophils.

73 Cysteinyl leukotrienes (cys-LTs) induce inflammation thr

74 Cysteinyl leukotrienes (cys-LTs) induce inflammatory res

75 The cysteinyl leukotrienes (cys-LTs) LTC(4), LTD(4), and LTE

76 The cysteinyl leukotrienes (cys-LTs) mediate both acute and

77 The cysteinyl leukotrienes (cys-LTs), leukotriene (LT) C(4),

78 The cysteinyl leukotrienes (cys-LTs), leukotriene C4 (LTC4),

79 stimulated a rapid and robust production of cysteinyl leukotrienes (cys-LTs), proinflammatory lipid

80 Although arachidonic acid metabolites, cysteinyl leukotrienes (cys-LTs; leukotriene [LT] C4, LT

81 ported in coculture generated low amounts of cysteinyl-leukotrienes (cys-LT) after FcepsilonRI-depend

82 Cysteinyl-leukotrienes (cys-LT) were measured by enzyme

83 -IgE or SCF and the generation of histamine, cysteinyl-leukotrienes (cys-LTs) and prostaglandin D(2)

84 We measured cysteinyl-leukotrienes (cys-LTs), prostaglandin E(2) (PG

85 ast, are potent and selective antagonists of cysteinyl leukotriene (cysLT) activity.

86 Tryptase and cysteinyl leukotriene (cysLT) levels were measured in na

87 flammatory cells, LTA4 is converted into the cysteinyl leukotriene (cysLT) LTC4, which is converted i

88 Cysteinyl leukotriene (cysLT) overproduction is a hallma

89 human mast cell line (LUVA) as determined by cysteinyl leukotriene (CysLT) production.

90 afirlukast is an orally active and selective cysteinyl leukotriene (cysLT) receptor antagonist.

91 rolled clinical trials have established that cysteinyl leukotriene (cysLT) receptor antagonists and 5

92 We found that both cysteinyl leukotriene (CysLT) receptors, CysLT(1) and Cy

93 model is reversible by administration of the cysteinyl leukotriene (CysLT)1 receptor antagonist monte

94 patients with asthma and may participate in cysteinyl leukotriene (CysLT; C(4), D(4), and E(4)) synt

95 We investigated whether cysteinyl leukotrienes (cysLT) are intracrine signal tra

96 ion was evaluated as Ca2+ flux, secretion of cysteinyl leukotrienes (CysLT), and eosinophil-derived n

97 tion of partner receptors (nucleotide P2Y12, cysteinyl-leukotriene CysLT1) to reconstitute the elusiv

98 et release of histamine (29.8 +/- 10.8%) and cysteinyl leukotrienes (cysLTs) (31.4 +/- 8.7 ng/10(6) b

99 Because cysteinyl leukotrienes (cysLTs) are also produced during

100 Cysteinyl leukotrienes (cysLTs) are bronchoconstricting

101 Cysteinyl leukotrienes (cysLTs) are important mediators

102 The cysteinyl leukotrienes (CysLTs) are important mediators

103 Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (cysLTs) are lipid mediators deri

104 The proinflammatory and vascular actions of cysteinyl leukotrienes (CysLTs) are mediated by 2 recept

105 The cysteinyl leukotrienes (CysLTs) are potent biological me

106 Cysteinyl leukotrienes (CysLTs) are potent lipid mediato

107 Leukotriene E4 (LTE4) the most stable of the cysteinyl leukotrienes (cysLTs) binds poorly to classica

108 Cysteinyl leukotrienes (CysLTs) contribute to asthma pat

109 Aerosolized cysteinyl leukotrienes (CysLTs) elicit migration of eosi

110 Cysteinyl leukotrienes (cysLTs) facilitate mucosal type

111 The cysteinyl leukotrienes (CysLTs) have been implicated in

112 nstrictive and proinflammatory properties of cysteinyl leukotrienes (cysLTs) in allergic asthma media

113 Cysteinyl leukotrienes (cysLTs) mediate vascular leakage

114 ctures show that the N-terminal domain binds cysteinyl leukotrienes (cysLTs) with high affinities (50

115 Cysteinyl leukotrienes (cysLTs), 5-lipoxygenase pathway

116 r of the airways, involves overproduction of cysteinyl leukotrienes (cysLTs), activation of airway ma

117 thma, tissue eosinophilia, overproduction of cysteinyl leukotrienes (cysLTs), and respiratory reactio

118 eukotriene E4 (LTE4), the most stable of the cysteinyl leukotrienes (cysLTs), binds poorly to classic

119 Large amounts of cysteinyl leukotrienes (cysLTs), classically known as a

120 In contrast, cysteinyl leukotrienes (cysLTs), important proinflammato

121 Cysteinyl leukotrienes (cysLTs), including leukotriene (

122 The cysteinyl leukotrienes (cysLTs), leukotriene (LT) C(4),

123 Cysteinyl leukotrienes (cysLTs), leukotriene C4 (LTC4),

124 contractile and inflammatory actions of the cysteinyl leukotrienes (CysLTs), LTC(4), LTD(4), and LTE

125 is unclear whether lipid mediators, such as cysteinyl leukotrienes (CysLTs), which are present in as

126 step in the formation of eicosanoids such as cysteinyl leukotrienes (CysLTs).

127 onstitutive and aspirin-induced secretion of cysteinyl leukotrienes (CysLTs).

128 capable of both producing and responding to cysteinyl leukotrienes (CystLTs), allowing for the killi

129 Cysteinyl leukotrienes D(4) and E(4) and PGD(2) also ind

130 Herein we report that uracil nucleotides and cysteinyl leukotrienes do not activate human, mouse, or

131 Measurement of the release of histamine and cysteinyl leukotrienes documented that this bronchoprote

132 The combination of PGD2 and cysLTs (notably cysteinyl leukotriene E4 [LTE4]) enhances TH2 cytokine p

133 ils, when activated, become major sources of cysteinyl leukotrienes, eicosanoid mediators pertinent t

134 st cell precursors and selectively increased cysteinyl leukotriene formation by mast cells in a manne

135 first time, that the phagosome is a site of cysteinyl leukotriene formation.

136 ar lavage fluid cells, prostaglandin D2, and cysteinyl leukotrienes from hyperventilated airways pret

137 on the ability of oxidative stress to alter cysteinyl leukotriene generation.

138 that is responsible for the biosynthesis of cysteinyl leukotrienes, has been deleted by targeted gen

139 These data indicate that the cysteinyl leukotrienes have a clinically significant rol

140 form LTC4, the parent of the receptor active cysteinyl leukotrienes implicated in the pathobiology of

141 to produce LTC4, the parent compound of the cysteinyl leukotrienes, important mediators of asthma.

142 Using immunostaining for the cysteinyl leukotrienes in carbodiimide-fixed cells, we s

143 We investigated roles of cysteinyl leukotrienes in mediating eosinophil trafficki

144 entify previously unrecognized roles for the cysteinyl leukotrienes in regulating the pulmonary traff

145 associated with the levels of histamine and cysteinyl leukotrienes in the airways.

146 farinae-elicited IL-6, IL-23, TNF-alpha, and cysteinyl leukotrienes in the lung.

147 These data suggest an important role for cysteinyl leukotrienes in the pathogenesis of chronic al

148 hilia and nonsignificant elevations of total cysteinyl leukotrienes in the sputum.

149 The metabolism of cysteinyl leukotrienes in vivo and the pathophysiologica

150 te the selective role of LTB4, as opposed to cysteinyl-leukotrienes, in murine models of inflammation

151 ility (RVP) was demonstrated using a bespoke cysteinyl leukotriene induced rodent model.

152 d urinary leukotriene E(4) levels indicating cysteinyl leukotriene inflammation can differentiate LAB

153 , ATLa treatment led to marked reductions in cysteinyl leukotrienes, interleukin-4 (IL-4), and IL-10,

154 cts: 5-,12-,15-hydroxyeicosatetraenoic acid, cysteinyl leukotrienes, leukotriene B4 , 11-dehydro-thro

155 The cysteinyl leukotrienes-leukotriene C4(LTC4), leukotriene

156 Pharmacological inhibition of cysteinyl leukotrienes, lipoxygenated products of arachi

157 We studied the effects of LPS on cysteinyl leukotriene (LT) synthesis and LTC(4) synthase

158 ding the production of Th2 cytokines and the cysteinyl leukotriene LTC(4).

159 ice, but migration was restored by exogenous cysteinyl leukotrienes LTC(4) or LTD(4).

160 tes 20-hydroxy-LTB4 and 20-carboxy-LTB4, the cysteinyl leukotriene LTC4, the 15-lipoxygenase product

161 d lipoxygenase products of arachidonic acid, cysteinyl leukotrienes (LTs), contribute to E. coli K1 i

162 poxygenated metabolites of arachidonic acid, cysteinyl leukotrienes (LTs).

163 lipid inflammatory mediators comprising the cysteinyl leukotrienes (LTs; LTC4, LTD4, and LTE4), only

164 triad of preclinical areas of investigation-cysteinyl leukotrienes, mast cells, and complement-with

165 We conclude that the early release of cysteinyl leukotrienes may contribute to the fall in tra

166 and increasing alveolar fluid reabsorption, cysteinyl leukotrienes may, in part, have a beneficial r

167 4, the biosynthetic parent of the additional cysteinyl leukotriene metabolites.

168 ompared with their classic substrates in the cysteinyl leukotriene metabolome.

169 e plasma membrane receptors for either LTB4, cysteinyl-leukotrienes, or both.

170 ccompanied by a surge in bronchoconstrictory cysteinyl leukotrienes produced at the expense of LTB4 i

171 polymorphism was associated with changes in cysteinyl leukotriene production, lung function, airway

172 This resulted in further cysteinyl leukotriene production, triggering a positive

173 s in s/s mice were associated with increased cysteinyl-leukotriene production in vivo and in AMs in v

174 have been described; the mechanisms by which cysteinyl leukotrienes promote the development of inflam

175 In vitro, these cysteinyl leukotrienes promoted optimal chemotaxis to th

176 abolites of vasoactive molecules showed that cysteinyl leukotrienes, prostacyclin metabolites, and PG

177 We measured histamine, cysteinyl-leukotrienes, prostanoids (prostaglandin D2 an

178 Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT(1)R) are efficacio

179 oth murine and human fibrocytes express both cysteinyl leukotriene receptor (CysLT) 1 and CysLT2.

180 ndent increase in cell-surface expression of cysteinyl leukotriene receptor 1 (CysLT1) as determined

181 Furthermore, LTD4 plus PGE2, through cysteinyl leukotriene receptor 1 (CysLT1R) and E-prostan

182 bute to asthma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R).

183 "proatopic" neutrophil subset that expressed cysteinyl leukotriene receptor 1 (CysLTR1) and produced

184 human T(H)2 cells might selectively express cysteinyl leukotriene receptor 1 (CYSLTR1) mRNA.

185 We functionally assessed cysteinyl leukotriene receptor 1 protein (CysLT(1)) expr

186 TH2 cells, and montelukast, an antagonist of cysteinyl leukotriene receptor 1.

187 s and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln

188 Stimulation of the cysteinyl leukotriene receptor activated CRAC channels a

189 zed by some as a dualistic uracil nucleotide/cysteinyl leukotriene receptor and by others as inactive

190 stigated the effectiveness of montelukast, a cysteinyl leukotriene receptor antagonist, in the treatm

191 The use of cysteinyl leukotriene receptor antagonists (LTRAs) for a

192 Leukotriene synthesis inhibitors and cysteinyl leukotriene receptor antagonists have shown ef

193 y, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists.

194 ve characterized the gene structure of human cysteinyl leukotriene receptor type I (cysLT(1)R).

195 ing montelukast (an antagonist of the type 1 cysteinyl leukotriene receptor) also inhibited E. coli i

196 Two classes of cysteinyl leukotriene receptor, CysLT(1) and CysLT(2), h

197 e cloning and characterization of the second cysteinyl leukotriene receptor, CysLT(2), a 346-amino ac

198 ted with a leukotriene B4 receptor but not a cysteinyl-leukotriene receptor antagonist.

199 mice could be blocked using a pharmacologic cysteinyl-leukotriene receptor antagonist.

200 Leukotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotriene receptors (CYSLTR1 and CYSLTR2) co

201 e inflammatory cells and their expression of cysteinyl leukotriene receptors 1 and 2 (CysLT(1) and Cy

202 antiangiogenic small molecule antagonist of cysteinyl leukotriene receptors 1 and 2 (CysLT1 and CysL

203 rectly target VEGF receptors but antagonizes cysteinyl leukotriene receptors 1 and 2 (CysLT1-2) at mi

204 ammatory factor that acts on plasma membrane cysteinyl leukotriene receptors.

205 rus expression, T-cell death, and eosinophil cysteinyl leukotriene release.

206 The field of cysteinyl leukotriene research has moved forward conside

207 made in three areas: genetic control of the cysteinyl leukotriene response, in which alterations in

208 exercise challenge, histamine, tryptase, and cysteinyl leukotrienes significantly increased and prost

209 We conclude that cysteinyl leukotrienes stimulate conjunctival goblet cel

210 1/2, cytosolic phospholipase A(2) alpha, and cysteinyl-leukotriene synthesis confers resistance to s/

211 bstance of anaphylaxis was composed of three cysteinyl leukotrienes that act in the inflammatory resp

212 (4)S) is responsible for the biosynthesis of cysteinyl leukotrienes that participate in allergic and

213 The de novo synthesis of cysteinyl leukotrienes, TNFalpha, CXCL8, CCL2, CCL3, and

214 ut the contributions of mediators other than cysteinyl leukotrienes to aspirin reactions and to the t

215 Cysteinyl leukotrienes activate the cysteinyl leukotriene type 1 receptor (CysLT1R) to regul

216 diating the leukotriene responses in asthma, cysteinyl leukotriene type 1 receptor (CysLT1R), have no

217 inic and H1 histamine receptor and expressed cysteinyl leukotriene type 1 receptor in human embryonic

218 G-protein-coupled cysteinyl leukotriene type I (CysLT1) receptors regulate

219 t cytoplasmic Ca(2+) oscillations induced by cysteinyl leukotriene type I receptor activation run dow

220 ations can be evoked by modest activation of cysteinyl leukotriene type I receptors by the physiologi

221 The cysteinyl leukotriene type I receptors desensitize throu

222 Here, we show that following stimulation of cysteinyl leukotriene type I receptors in rat basophilic

223 3) RNAi knockdown of cysteinyl leukotriene type I receptors on resting cells

224 2) Block of cysteinyl leukotriene type I receptors on resting mast c

225 The synthesis of cysteinyl-leukotrienes was reduced and that of PGE(2) en

226 GE2 were reduced in COX-1-/- airways whereas cysteinyl leukotrienes were elevated in COX-2-/- airways

227 sharp contrast, mean levels of prophlogistic cysteinyl leukotrienes were increased in samples from se

228 n and the accompanying in vivo generation of cysteinyl leukotrienes were markedly attenuated in group

229 FLAP), but lacked LTC4S and did not generate cysteinyl leukotrienes when stimulated with 20 mumol/L c

230 LTC4 is the parent molecule of the cysteinyl leukotrienes, which are recognized for their p

231 ablysin-15 was found to bind proinflammatory cysteinyl leukotrienes with submicromolar affinities.